Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.

Gilead Sciences, Inc., 4611 University Drive, Durham, North Carolina 27707, USA.
AIDS Research and Human Retroviruses (Impact Factor: 2.46). 09/2007; 23(8):988-95. DOI: 10.1089/aid.2006.0310
Source: PubMed

ABSTRACT The presence of drug-associated mutations among ART-naive, HIV-1(+) patients may compromise the response to antiviral therapy. We evaluated the effect of preexisting drug-associated resistance mutations to the response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV). Study FTC-301A compared emtricitabine once daily (QD) with stavudine twice daily in combination with didanosine and efavirenz in ART-naive patients. Genotypic analysis was performed on baseline plasma HIV-1 RNA for all available samples and at time of virologic failure (VF). Drug resistance mutations present at baseline were evaluated as predictors of VF using logistic regression. VF rates were compared between subgroups using a two-sided exact test. Baseline drug resistance mutations were observed in 90/546 (16.5%) patients: 56/90 (62.2%) with nonnucleoside analogue (NNRTI) mutations and 42/90 (46.6%) with nucleoside analogue mutations. In a stepwise, multiple regression analysis, the presence of the K103N mutation at initiation of therapy was associated with VF in both arms (p = 0.001), however, there was a higher incidence of VF in the stavudine arm compared to the emtricitabine arm regardless of the presence or absence of mutations at baseline (p = 0.001). In this study, the presence of drug-associated resistance mutations in ART-naive patients was significantly correlated with subsequent development of virologic failure underscoring the utility of testing for resistance in addition to the use of potent and well-tolerated first line regimens in treatment-naive patients.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The prevalence of HIV drug resistance varies with geographic location, year, and treatment exposure. This study generated yearly estimates of non-nucleotide reverse transcriptase inhibitor (NNRTI) resistance in treatment-naïve (TN) and treatment-experienced (TE) patients in the United States (US), Europe (EU), and Canada. Methods: Studies reporting NNRTI resistance identified in electronic databases and 11 conferences were analyzed in three groups: 1) TN patients in one of four geographic regions (US, Canada, EU countries with larger surveillance networks ["EU1"], and EU countries with fewer data ["EU2"]); 2) TE patients from any region and 3) TN patients failing NNRTI-based treatments in clinical trials. Results: Analysis data included 158 unique studies from 22 countries representing 84 cohorts of TN patients, 21 cohorts of TE patients, and eight trials reporting resistance at failure. From 1995-2000, resistance prevalence in TN patients increased in US and EU1 from 3.1% to 7.5% and 0.8% to 3.6%, respectively. Resistance in both regions stabilized in 2006 onwards. Little resistance was identified in EU2 before 2000, and increased from 2006 (5.0%) to 2010 (13.7%). One TN Canadian study was identified and reported resistance of 8.1% in 2006. Half of TN clinical trial patients had resistance after treatment failure at weeks 48-144. Resistance in TE patients increased from 1998 (10.1%) to 2001 (44.0%), then decreased after 2004. Conclusions: Trends in NNRTI resistance among TN patients show an increased burden in the US and some EU countries compared to others. These findings signify a need for alternate 1st-line treatments in some regions.
    AIDS Research and Human Retroviruses 06/2014; 30(8). DOI:10.1089/AID.2013.0262 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. Entecavir therapy often reduces hepatitis B virus (HBV) DNA to an undetectable level, but HBV DNA remain detectable in some patients. We investigated whether baseline HBV reverse transcriptase (rt) polymorphism and quasispecies complexity and diversity were associated with treatment response.Methods. Pre-treatment HBV DNA levels, HBV rt sequence, serology, and quasispecies complexity and diversity from 305 entecavir-treated patients were determined. These data were tested for their association with year one virological outcome, defined by optimal response (undetectable HBV DNA; ≤12 IU/mL) or partial response (detectable HBV DNA).Results. Four rt variants were more frequently detected in the 64 partial responders than in the 241 optimal responders (all P<.05). Multivariate analysis revealed that high baseline HBV DNA (P<.0001; odds ratio [OR]=2.32), hepatitis B e antigen (HBeAg)-positivity (P<.001; OR=3.70) and rt124N (P=.002; OR=3.06) were associated with partial entecavir response. Compared with the optimal responders, the partial responders had a lower quasispecies complexity and diversity.Conclusions. Apart from the known factors (high baseline HBV DNA, HBeAg-positivity), a novel single nucleotide polymorphism (rt124N) and lower quasispecies complexity and diversity were associated with partial entecavir response at year 1.
    The Journal of Infectious Diseases 03/2014; DOI:10.1093/infdis/jiu133 · 5.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The use of drug combinations has revolutionized the treatment of HIV but there is no equivalent combination product that exists for prevention, particularly for topical HIV prevention. Strategies to combine chemically incompatible agents may facilitate the discovery of unique drug-drug activities, particularly unexplored combination drug synergy. We fabricated two types of nanoparticles, each loaded with a single antiretroviral (ARV) that acts on a specific step of the viral replication cycle. Here we show unique combination drug activities mediated by our polymeric delivery systems when combined with free tenofovir (TFV). Methodology/Principal Findings Biodegradable poly(lactide-co-glycolide) nanoparticles loaded with efavirenz (NP-EFV) or saquinavir (NP-SQV) were individually prepared by emulsion or nanoprecipitation techniques. Nanoparticles had reproducible size (d ∼200 nm) and zeta potential (-25 mV). The drug loading of the nanoparticles was approximately 7% (w/w). NP-EFV and NP-SQV were nontoxic to TZM-bl cells and ectocervical explants. Both NP-EFV and NP-SQV exhibited potent protection against HIV-1 BaL infection in vitro. The HIV inhibitory effect of nanoparticle formulated ARVs showed up to a 50-fold reduction in the 50% inhibitory concentration (IC50) compared to free drug. To quantify the activity arising from delivery of drug combinations, we calculated combination indices (CI) according to the median-effect principle. NP-EFV combined with free TFV demonstrated strong synergistic effects (CI50 = 0.07) at a 1∶50 ratio of IC50 values and additive effects (CI50 = 1.05) at a 1∶1 ratio of IC50 values. TFV combined with NP-SQV at a 1∶1 ratio of IC50 values also showed strong synergy (CI50 = 0.07). Conclusions ARVs with different physicochemical properties can be encapsulated individually into nanoparticles to potently inhibit HIV. Our findings demonstrate for the first time that combining TFV with either NP-EFV or NP-SQV results in pronounced combination drug effects, and emphasize the potential of nanoparticles for the realization of unique drug-drug activities.
    PLoS ONE 04/2013; 8(4):e61416. DOI:10.1371/journal.pone.0061416 · 3.53 Impact Factor